{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:01:23Z","timestamp":1781334083567,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11899-021-00659-9","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T12:24:14Z","timestamp":1633609454000},"page":"509-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2180-7562","authenticated-orcid":false,"given":"Angela","family":"Canadeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Fournogerakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Zook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"11","key":"659_CR1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O\u2019Brien SG, Fo Guilhot, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457.","journal-title":"N Engl J Med"},{"issue":"6","key":"659_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ajh.22019","volume":"86","author":"P Ganesan","year":"2011","unstructured":"Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86(6):471\u20134. https:\/\/doi.org\/10.1002\/ajh.22019.","journal-title":"Am J Hematol"},{"issue":"14","key":"659_CR3","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.26.3087.","journal-title":"J Clin Oncol"},{"issue":"22","key":"659_CR4","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401\u201311. https:\/\/doi.org\/10.1182\/blood-2008-12-196543.","journal-title":"Blood"},{"issue":"5","key":"659_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/phar.1399","volume":"34","author":"DA McCue","year":"2014","unstructured":"McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy. 2014;34(5):481\u201394. https:\/\/doi.org\/10.1002\/phar.1399.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"659_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/1078155215608523","volume":"22","author":"MS Lam","year":"2016","unstructured":"Lam MS, Cheung N. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract. 2016;22(6):741\u20138. https:\/\/doi.org\/10.1177\/1078155215608523.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"659_CR7","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1200\/JOP.17.00039","volume":"14","author":"B Muluneh","year":"2018","unstructured":"\u2022\u2022Muluneh B, Schneider M, Faso A, Amerine L, Daniels R, Crisp B, et al. Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program. J Oncol Pract. 2018;14(6):e324\u201334. https:\/\/doi.org\/10.1200\/JOP.17.00039Outlines the major impact a pharmacist-led oral chemotherapy management program can have on improving patient knowledge, adherence, and possibly CML response rates.","journal-title":"J Oncol Pract"},{"issue":"5","key":"659_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/1078155217703792","volume":"24","author":"KP Morgan","year":"2018","unstructured":"\u2022\u2022Morgan KP, Muluneh B, Deal AM, Amerine LB. Impact of an integrated oral chemotherapy program on patient adherence. J Oncol Pharm Pract. 2018;24(5):332\u20136. https:\/\/doi.org\/10.1177\/1078155217703792Reveals how an integrated, pharmacist-led oral chemotherapy program , in collaboration with their internal specialty pharmacy colleagues, had high medication possession ratios for patients that filled at the institution\u2019s specialty pharmacy.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"659_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298\u2013305. https:\/\/doi.org\/10.1200\/JCO.2016.68.2914.","journal-title":"J Clin Oncol"},{"key":"659_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5774","author":"E Atallah","year":"2020","unstructured":"Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5774.","journal-title":"JAMA Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00659-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T02:18:23Z","timestamp":1635905903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00659-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00659-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"8 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Angela Canadeo, Mary Fournogerakis, and Felicia Zook declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article contains no studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}